TOP > 外国特許検索 > HIGH-DENSITY LIPOPROTEIN, AND DELIVERY OF DRUG TO POSTERIOR SEGMENT OF EYE BY OCULAR INSTILLATION OF SAID CYTOPHILIC PEPTIDE-FUSED HIGH-DENSITY LIPOPROTEIN

HIGH-DENSITY LIPOPROTEIN, AND DELIVERY OF DRUG TO POSTERIOR SEGMENT OF EYE BY OCULAR INSTILLATION OF SAID CYTOPHILIC PEPTIDE-FUSED HIGH-DENSITY LIPOPROTEIN

外国特許コード F180009639
整理番号 4734
掲載日 2018年11月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP086203
国際公開番号 WO 2016104690
国際出願日 平成27年12月25日(2015.12.25)
国際公開日 平成28年6月30日(2016.6.30)
優先権データ
  • 特願2014-263018 (2014.12.25) JP
発明の名称 (英語) HIGH-DENSITY LIPOPROTEIN, AND DELIVERY OF DRUG TO POSTERIOR SEGMENT OF EYE BY OCULAR INSTILLATION OF SAID CYTOPHILIC PEPTIDE-FUSED HIGH-DENSITY LIPOPROTEIN
発明の概要(英語) The purpose of the present invention is to provide a novel system for the delivery of a drug to a posterior segment of the eye. The present invention relates to: a cytophilic peptide-fused high-density lipoprotein (cHDL) which can be used as a carrier for the delivery of a drug to a posterior segment of the eye; a method for producing the cytophilic peptide-fused high-density lipoprotein; a system of the delivery of a drug to a posterior segment of the eye, a pharmaceutical composition, and a system of the delivery of a drug to a posterior segment of the eye, each of which utilizes the cytophilic peptide-fused high-density lipoprotein; and a method for diagnosing, preventing or treating posterior ocular disease.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, diabetic retinopathy and age related macular degeneration of a disease associated with the posterior eye segment such as intravitreal injection of the drug has been performed. Such local administration method is invasive, reliably direct drug into the eye for injecting a therapeutic effect can be expected on the other hand, the risk of endophthalmitis by injection of injection must be repeatedly conducted troublesome has been regarded as a problem. However, the eye into the eye from the outside control mass transport due to the presence of the barrier function, such as by eye drops and non-invasively through the administration is by intravenous administration, is not easy to reach the drug into the eye, in particular, drug delivery to posterior eye segment such as the retina is very low efficiency. Intraocular drug delivery shown in Fig. 1 various routes of administration.
In order to overcome this problem, drug carrier using the ophthalmic drug delivery by the carriers are attempts have been made. Among them, from biological material the biological nano-materials may include a carrier configured defense reaction does not readily occur in order to predict that, by having the kinetic properties of the nano materials prolong duration of efficacy is expected and the like can be cited as advantages. In the present invention, lipid transport in the blood of the living body mainly responsible for the high-density lipoprotein (HDL) nano material with attention paid to. The particle size of nanometers to several hundreds of HDL (nm) as small as less than about, moreover by protein engineering techniques, cell affinity activity, such as integrated vascular endothelial cells, various functions can be deposited to the HDL, ophthalmic drug delivery to posterior eye segment by carrier suitable as expected.
The current applied to an ophthalmic drug carriers include, for reaching a posterior eye segment liposomes is known (patent document 1 and 2). The posterior eye segment for reaching a in a liposome, the fluorescent dye coumarin -6 that are included in the liposomes, can be obtained by measuring their fluorescence intensity, it was confirmed that the drug delivery to posterior eye segment has been known.
On the other hand, in a liposome for reaching a trailing eye, each time with a reduced size, the arrival of the liposome to the posterior eye segment is increased, as a result agent is accumulated is expected and also improves has been reported (non-patent document 1), the size of the ophthalmic drag carrier reports suggest not more than 20 nm (non-patent document 2) also. However, generally less than 100 nm has been reported that the size of the liposomes can be made small. Therefore, drug delivery for the purpose of improving the efficiency, reduction of the size of the nanomaterial can be expected to develop a new biological material is demanded.
Affinity peptides is fuzed to a high-density lipoprotein (cHDL), anti-malignant tumor cell is intended for intracellular delivery, heretofore known (non-patent document 3), including HDL lipoprotein particle size for 100 nm or less, as eye drops and which has a drug delivery is not known.
In the high-density lipoprotein (HDL), functions such as cell affinity peptide by fuzing peptide, high-density lipoprotein itself fuzed to obtain a new kinetic, functional peptide itself also fusion peptide having a biological activity including high density lipoprotein (HDL) may be applied to the one could expect.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • SUDA, Kenji
  • MURAKAMI, Tatsuya
  • YOSHIMURA, Nagahisa
  • GOTOH, Norimoto
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close